Protocol Ledger

NCT06300177 · Phase III · RECRUITING

D-1553 Tablet Versus Docetaxel Injection for KRAS G12C Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Standard Therapy Failure

Interventional Phase III clinical trial protocol NCT06300177 sponsored by Chia Tai Tianqing Pharmaceutical Group Co in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-03-28 Enrollment: 522 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06300177
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)522 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06300177
Protocol FieldVerified Registry Value
NCT IdentifierNCT06300177
Consolidated Lead SponsorChia Tai Tianqing Pharmaceutical Group Co
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment522 participants (ESTIMATED)
Registered Start Date2024-03-28
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI